Somerset-based Catalent Inc., a global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products, announced Thursday the appointment of Karen Flynn as president of biologics and chief commercial officer.
Flynn also joins the company’s executive leadership team and will report to Alessandro Maselli, Catalent’s president and chief operating officer. She takes on the role previously held by Barry Littlejohns, who will be retiring.
Karen arrives during a period of strong growth both in the biologics business and across the company as a whole …
– Alessandro Maselli, president and COO
Flynn will assume global responsibility for Catalent’s biologics business, including the several investments and expansions currently taking place, like a $200 million capital investment to expand drug substance manufacturing capacity in Madison, Wis. and drug product fill/finish capacity in Bloomington, Ind. She will also spearhead commercial excellence across the entire company.
“We welcome Karen back to Catalent in a role that allows her to use her extensive talents and experience as we deliver to our customers advanced, crucial pharmaceutical research and development services, as well as commercial supply,” said Maselli. “Karen arrives during a period of strong growth both in the biologics business and across the company as a whole, during which we are investing hundreds of millions of dollars in our biologics business and strengthening our commitment to ensuring that our customers have access to the best possible advanced biologic development technology and manufacturing solutions, from DNA through to clinical and commercial supply.”
Maselli added: “We would like to thank Barry, who has given more than three decades of service to the company and, in particular, led our initial efforts to expand our biologics drug substance, drug product, and gene therapy businesses.”
Additionally, Catalent said it promoted Mike Riley to region president, Biologics North America, and appointed Manja Boerman as region president, Biologics Europe, where each will lead all development, manufacturing, and commercial activity in their respective regions, in addition to growing Catalent Biologics’ business.
Pete Buzy will continue to lead Catalent’s Gene Therapy business, where, under his guidance, the company has been investing significantly in capacity, equipment and expertise needed to meet strong and growing demand for custom development and manufacturing of adeno-associated virus (AAV) vectors, next-generation vaccines and oncolytic viruses.